Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/162066
Title: Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)
Author: Mothe, Beatriz
Manzardo, Christian
Sanchez-Bernabeu, Alvaro
Coll, Pep
Morón-López, Sara
Puertas, Maria C.
Rosas-Umbert, Miriam
Cobarsi, Patricia
Escrig, Roser
Pérez Álvarez, Núria
Ruiz, Irene
Rovira, Cristina
Meulbroek, Michael
Crook, Alison
Borthwick, Nicola
Wee, Edmund G.
Yang, Hongbing
Miró Meda, José M.
Dorrell, Lucy
Clotet i Sala, Bonaventura
Martínez Picado, Francisco Javier
Brander, Christian
Hanke, Tomás
Keywords: Cèl·lules T
VIH (Virus)
Farmacologia
Vacunació
T cells
HIV (Viruses)
Pharmacology
Vaccination
Issue Date: 5-Jun-2019
Publisher: Elsevier
Abstract: Background Strong and broad antiviral T-cell responses targeting vulnerable sites of HIV-1 will likely be a critical component for any effective cure strategy. Methods BCN01 trial was a phase I, open-label, non-randomized, multicenter study in HIV-1-positive individuals diagnosed and treated during early HIV-1 infection to evaluate two vaccination regimen arms, which differed in the time (8 versus 24 week) between the ChAdV63.HIVconsv prime and MVA.HIVconsv boost vaccinations. The primary outcome was safety. Secondary endpoints included frequencies of vaccine-induced IFN-γ+ CD8+ T cells, in vitro virus-inhibitory capacity, plasma HIV-1 RNA and total CD4+ T-cells associated HIV-1 DNA. (NCT01712425). Findings No differences in safety, peak magnitude or durability of vaccine-induced responses were observed between long and short interval vaccination arms. Grade 1/2 local and systemic post-vaccination events occurred in 22/24 individuals and resolved within 3 days. Weak responses to conserved HIV-1 regions were detected in 50% of the individuals before cART initiation, representing median of less than 10% of their total HIV-1-specific T cells. All participants significantly elevated these subdominant T-cell responses, which after MVA.HIVconsv peaked at median (range) of 938 (73-6,805) IFN-γ SFU/106 PBMC, representing on average 58% of their total anti-HIV-1 T cells. The decay in the size of the HIV-1 reservoir was consistent with the first year of early cART initiation in both arms.
Note: Reproducció del document publicat a: https://doi.org/10.1016/j.eclinm.2019.05.009
It is part of: EClinicalMedicine, 2019, vol. 11, p. 65-80
URI: http://hdl.handle.net/2445/162066
Related resource: https://doi.org/10.1016/j.eclinm.2019.05.009
https://doi.org/10.1016/j.eclinm.2019.100250
ISSN: 2589-5370
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
693663.pdf2.92 MBAdobe PDFView/Open
695889.pdfCorrigendum246.13 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons